STAT1 and experimental autoimmune encephalomyelitis: In animal models of experimental autoimmune encephalomyelitis (EAE), baricitinib was confirmed to act as a JAK1/2 inhibitor, delays disease onset, mitigates symptom severity, and inhibits Th1/Th17 polarization alongside STAT1/3/4 phosphorylation.